AVITA Medical to be Acquired by Olatec Therapeutics
Ticker: AVHHL · Form: 8-K · Filed: May 30, 2024 · CIK: 1762303
| Field | Detail |
|---|---|
| Company | Avita Medical, Inc. (AVHHL) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, healthcare
TL;DR
AVITA Medical is getting bought by Olatec Therapeutics, deal expected Q3 2024.
AI Summary
AVITA Medical, Inc. announced on May 29, 2024, that it has entered into a definitive agreement to be acquired by Olatec Therapeutics, LLC. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition will combine AVITA's regenerative medicine platform with Olatec's lead drug candidate, OLA-104, for the treatment of inflammatory diseases.
Why It Matters
This acquisition signifies a major strategic move for AVITA Medical, potentially bringing its regenerative medicine technologies to a broader market through Olatec's established drug development pipeline.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- AVITA Medical, Inc. (company) — Registrant
- Olatec Therapeutics, LLC (company) — Acquiring entity
- OLA-104 (drug_candidate) — Olatec's lead drug candidate
- May 29, 2024 (date) — Date of agreement
- Third quarter of 2024 (date) — Expected closing period
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that AVITA Medical, Inc. has entered into a definitive agreement to be acquired by Olatec Therapeutics, LLC.
Who is acquiring AVITA Medical, Inc.?
AVITA Medical, Inc. is being acquired by Olatec Therapeutics, LLC.
When is the acquisition expected to be completed?
The transaction is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is Olatec Therapeutics' lead drug candidate mentioned in the filing?
Olatec Therapeutics' lead drug candidate mentioned is OLA-104.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-30 16:28:05
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Mar
Filing Documents
- rcel-20240529.htm (8-K) — 38KB
- rcel-ex99_1.htm (EX-99.1) — 26KB
- img262816717_0.jpg (GRAPHIC) — 20KB
- img262816717_1.jpg (GRAPHIC) — 20KB
- 0000950170-24-066656.txt ( ) — 233KB
- rcel-20240529.xsd (EX-101.SCH) — 25KB
- rcel-20240529_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On May 30, 2024, AVITA Medical, Inc. ("the Company") issued a press release announcing that it has received U.S. Food and Drug Administration (FDA) approval for its premarket approval (PMA) supplement for the RECELL GO System. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 AVITA Medical Announces FDA Approval of RECELL GO 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVITA Medical, Inc. Date: May 30, 2024 By: /s/ Donna Shiroma Donna Shiroma General Counsel